vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and FVCBankcorp, Inc. (FVCB). Click either name above to swap in a different company.
FVCBankcorp, Inc. is the larger business by last-quarter revenue ($16.9M vs $15.0M, roughly 1.1× CHAMPIONS ONCOLOGY, INC.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs 11.5%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $-2.0M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
CSBR vs FVCB — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $16.9M |
| Net Profit | $268.0K | — |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | 43.7% |
| Net Margin | 1.8% | — |
| Revenue YoY | 11.5% | 4377.5% |
| Net Profit YoY | -63.2% | — |
| EPS (diluted) | $0.02 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $16.9M | ||
| Q3 25 | $14.0M | $416.0K | ||
| Q2 25 | $12.4M | $15.8M | ||
| Q1 25 | $17.0M | $382.0K | ||
| Q4 24 | $13.5M | $378.0K | ||
| Q3 24 | $14.1M | $412.0K | ||
| Q2 24 | $14.0M | $415.0K | ||
| Q1 24 | $12.0M | $359.0K |
| Q4 25 | $268.0K | — | ||
| Q3 25 | $-436.0K | $5.6M | ||
| Q2 25 | $-1.8M | $5.7M | ||
| Q1 25 | $4.5M | $5.2M | ||
| Q4 24 | $728.0K | — | ||
| Q3 24 | $1.3M | $4.7M | ||
| Q2 24 | $-109.0K | $4.2M | ||
| Q1 24 | $-2.5M | $1.3M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 43.7% | ||
| Q3 25 | -3.8% | — | ||
| Q2 25 | -16.2% | 45.9% | ||
| Q1 25 | 26.4% | — | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | -1.9% | — | ||
| Q1 24 | -21.4% | — |
| Q4 25 | 1.8% | — | ||
| Q3 25 | -3.1% | 1341.1% | ||
| Q2 25 | -14.9% | 36.0% | ||
| Q1 25 | 26.4% | 1352.1% | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 9.3% | 1133.3% | ||
| Q2 24 | -0.8% | 1001.2% | ||
| Q1 24 | -21.1% | 373.3% |
| Q4 25 | $0.02 | $0.31 | ||
| Q3 25 | $-0.03 | $0.31 | ||
| Q2 25 | $-0.12 | $0.31 | ||
| Q1 25 | $0.31 | $0.28 | ||
| Q4 24 | $0.05 | $0.27 | ||
| Q3 24 | $0.09 | $0.25 | ||
| Q2 24 | $-0.01 | $0.23 | ||
| Q1 24 | $-0.19 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $253.6M |
| Total Assets | $30.2M | $2.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | — | ||
| Q3 25 | $10.3M | — | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $3.2M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $4.5M | — |
| Q4 25 | $4.2M | $253.6M | ||
| Q3 25 | $3.5M | $249.8M | ||
| Q2 25 | $3.8M | $243.2M | ||
| Q1 25 | $5.5M | $242.3M | ||
| Q4 24 | $681.0K | $235.4M | ||
| Q3 24 | $-332.0K | $230.8M | ||
| Q2 24 | $-1.9M | $226.5M | ||
| Q1 24 | $-2.1M | $220.7M |
| Q4 25 | $30.2M | $2.3B | ||
| Q3 25 | $30.5M | $2.3B | ||
| Q2 25 | $32.3M | $2.2B | ||
| Q1 25 | $30.6M | $2.2B | ||
| Q4 24 | $25.2M | $2.2B | ||
| Q3 24 | $24.9M | $2.3B | ||
| Q2 24 | $26.1M | $2.3B | ||
| Q1 24 | $26.8M | $2.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $23.9M |
| Free Cash FlowOCF − Capex | $-2.0M | $23.8M |
| FCF MarginFCF / Revenue | -13.1% | 140.7% |
| Capex IntensityCapex / Revenue | 1.6% | 0.3% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $40.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $23.9M | ||
| Q3 25 | $600.0K | $7.6M | ||
| Q2 25 | $6.9M | $3.3M | ||
| Q1 25 | $490.0K | $5.4M | ||
| Q4 24 | $-283.0K | $18.2M | ||
| Q3 24 | $311.0K | $4.7M | ||
| Q2 24 | $-1.8M | $1.6M | ||
| Q1 24 | $-919.0K | $7.2M |
| Q4 25 | $-2.0M | $23.8M | ||
| Q3 25 | $554.0K | $7.6M | ||
| Q2 25 | $6.6M | $3.3M | ||
| Q1 25 | $448.0K | $5.4M | ||
| Q4 24 | $-377.0K | $18.1M | ||
| Q3 24 | — | $4.6M | ||
| Q2 24 | $-1.8M | $1.5M | ||
| Q1 24 | $-1.0M | $7.1M |
| Q4 25 | -13.1% | 140.7% | ||
| Q3 25 | 4.0% | 1818.0% | ||
| Q2 25 | 53.5% | 20.8% | ||
| Q1 25 | 2.6% | 1413.6% | ||
| Q4 24 | -2.8% | 4786.0% | ||
| Q3 24 | — | 1121.8% | ||
| Q2 24 | -13.0% | 361.2% | ||
| Q1 24 | -8.4% | 1988.3% |
| Q4 25 | 1.6% | 0.3% | ||
| Q3 25 | 0.3% | 0.2% | ||
| Q2 25 | 2.0% | 0.1% | ||
| Q1 25 | 0.2% | 4.2% | ||
| Q4 24 | 0.7% | 37.3% | ||
| Q3 24 | 0.0% | 14.1% | ||
| Q2 24 | 0.0% | 12.8% | ||
| Q1 24 | 0.8% | 3.9% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | 0.11× | 1.05× | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | 1.00× | ||
| Q2 24 | — | 0.37× | ||
| Q1 24 | — | 5.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
FVCB
Segment breakdown not available.
